NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lexaria's Phase 1b Study GLP-1-H24-4 Additional Results and Implications
TL;DR
Lexaria's DehydraTECH platform shows superior safety and reduced side effects compared to Rybelsus, potentially offering a competitive edge in the GLP-1 drug delivery market.
The Phase 1b study demonstrated comparable efficacy in glucose and cholesterol control while achieving better safety profiles and body composition outcomes through Lexaria's DehydraTECH technology.
Lexaria's technology reduces adverse gastrointestinal effects and improves patient-reported quality of life, potentially making GLP-1 treatments more accessible and tolerable for those who need them.
Lexaria's study revealed that their DHT-CBD formulation lowered blood pressure in non-hypertensive participants, an unexpected finding that could expand treatment applications beyond weight management.
Found this article helpful?
Share it with your network and spread the knowledge!
This announcement provides additional secondary and exploratory endpoint final results from Lexaria's Phase 1b, 12-week chronic clinical study (GLP-1-H24-4), focusing on data from its DehydraTECH™ (DHT) study arms compared to a Rybelsus® control arm.
The positive results from this study are guiding Lexaria's 2026 R&D plans and business development initiatives, as clinical data is of paramount importance at their stage of development, showcasing the potential benefits of their DehydraTECH™ platform.
At week 16, rough parity was reached between the DHT arms and the Rybelsus® control, as no statistically significant treatment differences were observed in the changes from baseline for mean fasting glucose, cholesterol, and LDL cholesterol.
While both reduced body weight, the DHT-semaglutide arm showed a modest reduction in fat mass (-1.08 kg) and total mass (-1.40 kg) with minimal lean mass loss (-0.41 kg). The Rybelsus® control had greater reductions in fat mass (-3.55 kg) and total mass (-5.36 kg) but also a notably higher reduction in lean mass (-1.72 kg), suggesting DHT-semaglutide may achieve proportionally lower lean mass to fat mass reduction.
The DHT-CBD arm achieved meaningful reductions in blood pressure, with a mean change of -4.6 mmHg systolic and -4.0 mmHg diastolic at week 4, and reductions persisted at the week 16 follow-up, which is encouraging for Lexaria's interests in developing DHT-CBD for hypertension treatment.
The study was conducted by Lexaria Bioscience Corp. and was recently completed in Australia.
The blood pressure reductions in the DHT-CBD arm are very encouraging for Lexaria's separate program to develop DHT-CBD for treating hypertensive patients, for which the company has already received FDA clearance to conduct a Phase 1b study.
Lexaria is expecting exciting developments in 2026 and beyond, as the results from this study are already guiding their 2026 R&D and business development plans.
Curated from NewMediaWire
